Relay Therapeutics Q1 net loss $94.2M; cash $937.8M; RLY-2608 shows no Grade 3 hyperglycemia

Relay Therapeutics, Inc.

2023-Q1 EPS reported -$0.78 revenue$226,000

Net loss of $94.2M ($0.78 per share) vs $62.0M ($0.57) in Q1 2022; R&D expense $82.8M up from $51.7M.
Cash, equivalents and investments $937.8M vs ~$1B at Dec 31 2022; expected to fund operations into 2025.
Initial RLY-2608 data at AACR: no Grade 3 hyperglycemia/rash/diarrhea at target exposures; one confirmed partial response in breast cancer patient after cut-off.
RLY-5836 first-in-human trial initiated in April 2023 for PIK3CA-mutant solid tumors; RLY-2139 candidate selected, clinical start early 2024.
Full RLY-4008 dose escalation data accepted at ASCO 2023; expansion cohorts for RLY-2608 planned H2 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Relay Therapeutics, Inc. reported the first quarter of 2023 results: net income $94.2 million, EPS $0.78.

Period: the first quarter of 2023
Net income: $94.2 million
EPS: $0.78
Result: reported results

Exact text from the filing

Net loss was $94.2 million for the first quarter of 2023, or a net loss per share of $0.78, as compared to a net loss of $62.0 million for the first quarter of 2022, or a net loss per share of $0.57.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Relay Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-017857

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.